There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Achieve Life Sciences (ACHV – Research Report) and Better Therapeutics, Inc. (BTTX – Research Report) with bullish sentiments.
Achieve Life Sciences (ACHV)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Achieve Life Sciences, with a price target of $35.00. The company’s shares closed last Monday at $2.20, close to its 52-week low of $2.00.
According to TipRanks.com, Higgins is a 4-star analyst with an average return of
Achieve Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $35.00.
See today’s best-performing stocks on TipRanks >>
Better Therapeutics, Inc. (BTTX)
In a report released today, Keay Nakae from Chardan Capital maintained a Buy rating on Better Therapeutics, Inc., with a price target of $14.00. The company’s shares closed last Monday at $1.49, close to its 52-week low of $0.91.
According to TipRanks.com, Nakae is a 3-star analyst with an average return of
Currently, the analyst consensus on Better Therapeutics, Inc. is a Moderate Buy with an average price target of $14.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACHV:
- MAVERIX ANNOUNCES THIRD QUARTER 2022 RESULTS AND DECLARES QUARTERLY DIVIDEND
- Alamos Gold Extends High-Grade Gold Mineralization Beyond Mineral Reserves and Resources at Puerto Del Aire Deposit within Mulatos District
- AutoNation Announces Acquisition of Minority Ownership Stake in TrueCar, a Leading Automotive Digital Marketplace
- Castellum, Inc. Announces Strong Third Quarter Financial Results Including Record Revenue
- Needham Sticks to Its Buy Rating for Volta (VLTA)
